Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
- Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals
- What The Emerging Science Tells Us About Treating Obesity
- Exploring Functional Uses Of AI In Life Sciences
- Where Are They Now? Novo Nordisk
- Five Lessons For Creating The Drug Development Leaders Of Tomorrow
- Doubling Down On Biopharma’s Growing Skills Drought
- The Evolution Of Drug Packaging: Redefining Safety And Sustainability
- Reducing The Cost Of Cancer With Improved Diagnostics
COMPANIES TO WATCH
-
Companies To Watch: Antiva Biosciences
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
-
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
-
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
-
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
WHERE ARE THEY NOW
-
Where Are They Now? Novo Nordisk
In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
-
Where Are They Now? Ono Pharmaceuticals
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
Where Are They Now? Roivant
"Where Are They Now?" looks back, and forward, at companies and executives previously covered in Life Science Leader magazine.